XGene Regulatory Intelligence Center

Search the evidence. See the connection.

Find governed public regulatory signals and connect them to CMC, quality, inspection, remediation, XGene analysis, and consulting pathways.

Search IntelligenceInsights Hub
01SearchAgency, issue, system, product, or technical term.
02FacetDomain, content type, CMC discipline, and authority.
03ConnectOpen related analysis, resources, and services.
04ActMove into assessment or implementation when needed.

XGene Intelligence Discovery

Search governed XGene regulatory intelligence.

Use faceted discovery across public regulatory records, guidance, analysis, resources, case studies, intelligence briefs, and services.

Loading governed XGene intelligence…

Interpret before you act

A regulatory record is evidence—not the entire decision.

Use the connected XGene layers to understand what the source means for the technical system and what action, if any, is justified.

01

Source

Start with the actual authority, record, date, action, or guidance.

02

Technical context

Connect the signal to CMC, quality, manufacturing, laboratory, data, or inspection systems.

03

Pattern

Compare the signal with related XGene analysis and evidence already in the platform.

04

Action

Use the related service, resource, or assessment pathway only when the evidence supports it.

Advanced governed source toolsOpen the original XGene Platform search/filter interface

XGene Regulatory Intelligence Platform

Search regulatory findings, guidance, expert analysis, and practical resources.

Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.

435 results
FAQ

What should the drug product Quality Overall Summary explain beyond the composition table?

The QOS should function as a scientific argument, not merely repeat Module 3 headings. It should connect the Quality Target Product Profile to the critical quality attributes, explain why development decisions were made, show how the manufacturing process and controls assure performance, justify specifications, address container-closure and extractables/leachables considerations where relevant, and establish the scientific […]

View details →
FAQ

How can a company make its CMC knowledge more structured, reusable, and AI-ready?

AI readiness begins with information governance, not document generation. CMC knowledge should be managed as controlled, traceable data objects with defined terminology, metadata, version control, source references, and accountable subject-matter ownership. This allows the same approved knowledge to support submissions, change management, lifecycle activities, and future analytics without repeatedly rebuilding it from disconnected Word files, […]

View details →
FAQ

What should a regulated company evaluate under EU Annex 11 besides electronic signatures and audit trails?

A narrow Part 11-style review can miss several operational controls emphasized by Annex 11. Companies should evaluate supplier assessment and audit expectations, periodic review of validated systems, business-continuity arrangements, and control over data storage and ownership. These topics should be reflected in validation documentation, quality agreements, supplier oversight, system inventories, backup and recovery arrangements, and […]

View details →
FAQ

What does FDA expect from an OOS investigation beyond the initial laboratory assessment?

An initial laboratory assessment should determine whether a credible, documented laboratory cause exists, but it should not become a mechanism for stopping the investigation prematurely. When no assignable laboratory cause is established, the investigation should expand to manufacturing, sampling, materials, methods, equipment, related results, and potential batch or product impact. The organization should preserve the […]

View details →
FAQ

How is CAPA effectiveness different from simply closing a CAPA?

CAPA closure is an administrative status showing that assigned actions were completed. Effectiveness is an evidence-based conclusion that the actions corrected the underlying problem, reduced recurrence risk, and did not create unintended consequences. A meaningful effectiveness check should be linked to the original root cause and failure mode, use predefined acceptance criteria, cover an appropriate […]

View details →
FAQ

What should a data-integrity remediation program include beyond audit-trail review?

Audit-trail review is only one control within a broader data-governance system. A credible remediation program may need to define the scope and independence of retrospective review, establish a defensible review methodology, identify unofficial or shadow systems, assess access and role design, and confirm how data are created, processed, reviewed, retained, backed up, and retrieved. It […]

View details →
FAQ

What is the difference between a correction, an interim control, a root cause, a CAPA, and a retrospective review?

These elements serve different purposes and should not be blended together. A correction addresses the specific observed condition; an interim control protects operations while the investigation continues; root-cause analysis explains why the issue occurred; CAPA changes the system to prevent recurrence; and retrospective review determines whether the same weakness affected prior records, batches, products, or […]

View details →
FAQ

What should leadership do in the first 72 hours after receiving an FDA Form 483?

Leadership should resist the urge to begin drafting immediately. The first priority is to determine what FDA may be testing through each observation, reconstruct the evidence chain, identify affected products and systems, and establish clear ownership. A disciplined triage should distinguish immediate correction, interim control, root-cause work, CAPA, retrospective review, and longer-term remediation. The response […]

View details →
FAQ

Is the fastest FDA 483 response usually the strongest response?

Not necessarily. Speed matters, but a response prepared before the organization understands the underlying problem can commit the company to the wrong root cause, an incomplete CAPA, or an unrealistic timeline. A strong response is governed by evidence, risk, ownership, and execution feasibility. It should show that the company has contained immediate risk, investigated systemically, […]

View details →
Service

Biologics & Advanced Modalities CMC

XGene integrates process development, analytical strategy, control strategy, comparability, manufacturing readiness, validation and regulatory documentation so advanced programs can mature without disconnecting development science from the submission package.

Advanced Modality CMC
View details →
Service

Inspection Readiness & PAI Support

XGene evaluates whether the site can retrieve, explain and defend the records, controls, decisions and quality-system behavior an investigator is likely to test — then builds a controlled front-room and remediation plan around the gaps.

Inspection Readiness
View details →
Service

FDA 483 / Warning Letter & GMP Remediation

XGene structures FDA-response and remediation programs around evidence, root cause, containment, corrective action, effectiveness and sustainable quality-system control — not persuasive writing alone.

Warning Letter / 483 Response
View details →
Service

Data Integrity & Digital Quality

XGene examines the full evidence lifecycle — creation, attribution, review, modification, retention, transfer and use — so remediation addresses the system that creates unreliable records, not just the visible documentation symptom.

Data Integrity Remediation
View details →
Service

CMC Strategy, Module 3 & Submission Readiness

XGene connects development evidence, control strategy, analytical justification, manufacturing history and Module 3 authorship so the dossier tells one defensible technical story rather than a collection of independently written sections.

Regulatory CMC Strategy
View details →

Need the implication, not just the citation?

Connect the evidence to the technical decision.

Request an AssessmentExplore Services